Regulation and functions of the protein C anticoagulant pathway

Haematologica

Volumn 84, Issue 4, 1999, Pages 363-368

  Esmon, Charles T ^a,b   Gu, Jian Ming ^a   Xu, Jun ^c   Qu, Dongfeng ^c   Stearns Kurosawa, Deborah J ^c   Kurosawa, Shinichiro ^c  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c NONE

Author keywords

Anticoagulants; Protein C

Indexed keywords

ACTIVATED PROTEIN C; ENDOTOXIN; HIRUDIN; MESSENGER RNA; METALLOPROTEINASE; THROMBIN; THROMBOMODULIN;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CELL ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; LUPUS ERYTHEMATOSUS; NONHUMAN; PROTEIN BINDING; RAT; SEPSIS;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; PROTEIN C; RATS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 0032845209     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264:4743-6.
2. Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995; 270: 25336-9.
3. Bourin MC, Lundgren-Åkerlund E, Lindahl U. Isolation and characterization of the glycosaminoglycan component of rabbit thrombomodulin proteoglycan. J Biol Chem 1990;265:15424-31.
4. Egan JO, Kalafatis M, Mann KG. The effect of Arg306->Ala and Arg506->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Science 1997; 6: 2016-27.
5. Regan LM, Lamphear BJ, Huggins CF, Walker FJ, Fay PJ. Factor IXa protects factor Villa from activated protein C. J Biol Chem 1994; 269:9445-52.
6. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 1994; 269:18735-8.
7. Heeb MJ, España F, Griffin JH. Inhibition and complexation of activated protein C by two major inhibitors in plasma. Blood 1989; 73:446-54.
8. Scully MF, Toh CH, Hoogendoorn H, Manuel RP, Nesheim ME, Solymoss S, Giles AR. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α1-antitrypsin and α2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost 1993; 69:448-53.
9. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271:16603-8.
10. Uchiba M, Okajima K, Murakami K, Nawa K, Okabe H, Takatsuki K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 1995; 74:1265-70.
11. Hasegawa N, Kandra TG, Husari AW, et al. The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats. Am J Respir Crit Care Med 1996; 153:1831-7.
12. Uchiba M, Okajima K, Murakami K, et al. rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation. Am J Physiol 1997;273:L889-L894.
13. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-62.
14. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995; 5:141-8.
15. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations in myocardial infarction. Circulation 1997; 96:15-8.
16. Ohlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995; 85:330-6.
17. Norlund L, Holm J, Zoller B, Ohlin A-K. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost 1997; 77:248-51.
18. Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-91.
19. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93:10212-6.
20. Regan LM, Steams-Kurosawa DJ, Kurosawa S, Mollica J, Fukudome K, Esmon CT. The endothelial cell protein C receptor: Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J Biol Chem 1996; 271: 17499-503.
21. Taylor FB, Jr., Chang A, Esmon CT, D'Angelo A, Viganò D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E coli infusion in the baboon. J Clin Invest 1987; 79:918-25.
22. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87:642-7.
23. Grey ST, Hancock WW. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. J Immunol 1996; 156: 2256-63.
24. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997;272:L197-L202.
25. Laszik Z, Mitro A, Taylor FB, Jr., Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway. Circulation 1997; 96:3633-40.
26. Dreyfus M, Masterson M, David M, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995; 21:371-81.
27. Powars DR, Rogers ZR, Patch MJ, McGehee WG, Francis RB. Purpura fulminans in meningococcemia: Association with acquired deficiencies of proteins C and S [letter]. N Engl J Med 1987; 317:571-4.
28. Smith OP, White B, Vaughan D, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350:1590-3.
29. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995; 126:646-52.
30. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78:2249-52.
31. Xu J, Qu D, Esmon CT. Characterization of endothelial protein C receptor [abstract]. Vascular Biology '98 meeting 1998.
32. Xu J, Qu D, Esmon CT. Thrombin enhanced release of soluble EPCR mediated by metalloproteinases associated with caveolae [abstract]. Vascular Biology '98 meeting 1998.
33. Fukudome K, Kurosawa S, Stearns-Kurosawa DJ, He X, Rezaie AR, Esmon CT. The endothelial cell protein C receptor: Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 1996; 271:17491-8.
34. Smirnov MD, Safa O, Regan L, et al. A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J Biol Chem 1998; in press.
35. Regan LM, Mollica JS, Rezaie AR, Esmon CT. The interaction between the endothelial cell protein C receptor and protein C is dictated by the Gla domain of protein C. J Biol Chem 1997; 272:26279-84.
36. Beutler B, Cerami A. The history, properties, and biological effects of cachectin. Biochemistry 1988; 27: 7575-82.
37. Ding W, Gu J-M, Fukudome K, Laszik Z, Grammas P, Esmon CT. Upregulation of the message for rodent endothelial cell protein C receptor (EPCR) by endotoxin and thromoin [abstract]. Circulation 1996; 94: 1694.
38. Scarpati EM, DiCorleto PE. Identification of a thrombin response element in the human platelet-derived growth factor B-chain (c-sis) promoter. J Biol Chem 1996; 271:3025-32.
39. Gu JM, Esmon CT. Functional characterization of 5'-flanking region of the mouse endothelial protein C receptor (EPCR) gene [abstract]. Mol Biol Cell (Suppl) 1997; 8:228a.
40. Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 1997; 100: 411-8.
41. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Esmon CT. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998; 91:724-8.
42. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76:2024-9.